Correlative Study Between JAK2V617F Mutation And Thrombosis In Patients With Myeloproliferative Neoplasm

Objective：The aim of this study to investigate the correlation between JAK2V617Fmutation and thrombosis in patients with myeloproliferative neoplasm（MPN）anddifferences of Han and Uyghur patients. Methods：128cases of MPN patients in ourhospital from2008to2011were collected and the clinical features, laboratory, JAK2V617F gene mutations and thromboembolism events were retrospectively analyzed;Logistic regression analysis was used to analyze the risk factors of thrombosis between theJAK2V617F mutation, age, ethnicity, peripheral blood cells and vascular risk factors.Results：①JAK2V617F mutation was detected in93(72.6%) and thrombosis occurred in66（51.6%）of the128MPN patients. The overall incidence of thromboembolism eventswas62.4%(58/93) among the JAK2+MPN patients and compared to22.9%(8/35) inJAK2-MPN patients,(2=15.893， P＜0.05).②The study included Han and Uyghurminorities, the mutation rate and thrombosis occurrence76.3%(58/76)、55.3%（42/76）and67.3%（35/52）、46.2%（24/52）respectively. The difference of mutation rate andThrombosis occurrence among the two groups was not significant（2=1.261，P＞0.05、2=1.026，P＞0.05）.③The difference between incidence of thromboembolism events inJAK2+Han and Uyghur patients was significant respectively compared to JAK2-Han andUyghur patients (2=7.207,P=0.007;2=8.259, P=0.004).④Logistic regression showedthat patients with JAK2V617F mutation, age≥60, WBC≥15×109/L and vascular riskfactors were more vulnerable to thrombosis. Conclusion：We found that JAK2V617Fgene mutation occurs in large proportion of patients with MPN and patients withJAK2V617F mutation are more susceptible to thrombosis. They were no significantlydifference between Han and Uyghur patients both of mutation rate and thrombosisoccurrence according to this study. Patients with JAK2+, high average age, higher whiteblood cells and with cardiovascular risk factors were probably has higher rate ofthromboembolism events, can given early intervention about antithrombotic treatment.